RecruitingPhase 2NCT03801434
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Studying Hypereosinophilic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- William Shomali
- Principal Investigator
- William E Shomali, MDStanford Cancer Institute Palo Alto
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2028
Study locations (4)
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- OHSU Knight Cancer Institute, Portland, Oregon, United States
- University of Utah, Salt Lake City, Utah, United States
- Fred Hutchinson cancer research center, Seattle, Washington, United States
Collaborators
Incyte Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03801434 on ClinicalTrials.govOther trials for Hypereosinophilic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07275190The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic SyndromeFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT06477653Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE3NCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE3NCT04191304A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)AstraZeneca
- RECRUITINGNCT04538937Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing EosinophilsMedical University Innsbruck
- RECRUITINGNCT04018118Natural History of Hypereosinophilia and Hypereosinophilic SyndromesUniversity Hospital, Lille
- RECRUITINGNCT00091871A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE2NCT00044304Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeNational Institute of Allergy and Infectious Diseases (NIAID)